Juno Therapeutics, Inc., a biopharmaceutical company developing immunotherapies, has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company’s cell-therapy products. The facility, which is expected to come on line in early 2016, will support Juno’s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno’s pipeline, and the company’s first commercial products. Juno will continue to work with its existing contract manufacturing partners to augment its manufacturing capabilities.

Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date, according to the company.

Source: Juno Therapeutics